396 related articles for article (PubMed ID: 25638534)
1. Reimbursement of targeted cancer therapies within 3 different European health care systems.
Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
[TBL] [Abstract][Full Text] [Related]
2. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
5. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology.
Dankó D; Blay JY; Garrison LP
Health Policy; 2019 Dec; 123(12):1230-1236. PubMed ID: 31337514
[TBL] [Abstract][Full Text] [Related]
8. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
Kang J; Cairns J
BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
[TBL] [Abstract][Full Text] [Related]
9. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
11. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
12. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
13. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
Hoomans T; Severens JL; van der Roer N; Delwel GO
Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
[TBL] [Abstract][Full Text] [Related]
14. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic evaluation in Ireland: a review of the process.
Tilson L; O'Leary A; Usher C; Barry M
Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
[TBL] [Abstract][Full Text] [Related]
16. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
Cleemput I; van Wilder P; Huybrechts M; Vrijens F
Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences between five European drug reimbursement systems.
Franken M; le Polain M; Cleemput I; Koopmanschap M
Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
[TBL] [Abstract][Full Text] [Related]
18. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
Delwel GO; Sprenger MJ
Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
[TBL] [Abstract][Full Text] [Related]
19. The Pharmacoeconomic Evaluation Process in Ireland.
McCullagh L; Barry M
Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
[TBL] [Abstract][Full Text] [Related]
20. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
